Skip to main content
. 2020 Jul 24;24(2):198–203. doi: 10.4103/aian.AIAN_18_20

Table 1.

Clinical characteristics and immunotyping of cases with congenital muscular dystrophy

Parameter Merosin deficient CMD (n=15, 26.3%) Ullrich CMD (n=11, 19.2%) α-Dystroglycanopathy (n=7, 12.3%) Uncharacterized (n=24, 42.2%)
Mean age at presentation 3.7 years 5.3 years 6.3 years 7.2 years
M: F ratio 1.5:1 1.2:1 1.3:1 1.6:1
Mean creatinine kinase 1657 U/L Normal 2371 U/L 1233 U/L
MRI * White matter hyperintensities-8/8 Normal-2/2 pachygyria, lissencephaly. and cerebellar cyst-1/1 (WWS) White matter hyperintensities-3/3
Positive family history * 2/3 2/2 NA 2/6
Hypotonia 15 11 7 22
Motor delay 14 9 4 17
Myopathic facies 8 5 4 10
Soft velvety palms & soles 0 9 4 8
Multiple contractures 11 7 6 19
Distal joint hyperextensibility 1 9 1 12
Prominent calcaneum 2 4 3 5
Seizures 0 0 1 0
Laminin α2 Complete loss-15 Preserved Reduced-3 Preserved-4 Preserved
Laminin α5 Overexpression-7 Limited to blood vessels Limited to blood vessels Limited to blood vessels- 22 Overexpression-2
Laminin β1 Reduced-6 Preserved Preserved Preserved
Laminin γ1 Preserved Preserved Preserved Preserved
Collagen VI (A1,2,3) Preserved Complete loss-8 Sarcolemmal specific loss-3 Preserved Preserved
α-DG Absent-5 Reduced-2 Preserved
POMT1 Absent-1 (WWS) Preserved

* Denominator indicates the total number in which data was available, DG: Dystroglycan, CMD: Congenital muscular dystrophy, NA: Not available, WWS—Walker–Warburg syndrome